Johanna Hjalte1, Shakhawath Hossain2, Andreas Hugerth3, Helen Sjögren3, Marie Wahlgren1, Per Larsson2, Dan Lundberg4. 1. Food Technology, Engineering and Nutrition, Lund University, Box 124, 221 00 Lund, Sweden. 2. Department of Pharmacy, Drug Delivery, Uppsala University, Box 580, 751 23 Uppsala, Sweden. 3. Ferring Pharmaceuticals A/S, Amager Strandvej 405, 2770 Kastrup, Denmark. 4. CR Competence AB, Center for Chemistry and Chemical Engineering, Box 124, 221 00 Lund, Sweden.
Abstract
Understanding of peptide aggregation propensity is an important aspect in pharmaceutical development of peptide drugs. In this work, methodologies based on all-atom molecular dynamics (AA-MD) simulations and 1H NMR (in neat H2O) were evaluated as tools for identification and investigation of peptide aggregation. A series of structurally similar, pharmaceutically relevant peptides with known differences in aggregation behavior (D-Phe6-GnRH, ozarelix, cetrorelix, and degarelix) were investigated. The 1H NMR methodology was used to systematically investigate variations in aggregation with peptide concentration and time. Results show that 1H NMR can be used to detect the presence of coexisting classes of aggregates and the inclusion or exclusion of counterions in peptide aggregates. Interestingly, results suggest that the acetate counterions are included in aggregates of ozarelix and cetrorelix but not in aggregates of degarelix. The peptides investigated in AA-MD simulations (D-Phe6-GnRH, ozarelix, and cetrorelix) showed the same rank order of aggregation propensity as in the NMR experiments. The AA-MD simulations also provided molecular-level insights into aggregation dynamics, aggregation pathways, and the influence of different structural elements on peptide aggregation propensity and intermolecular interactions within the aggregates. Taken together, the findings from this study illustrate that 1H NMR and AA-MD simulations can be useful, complementary tools in early evaluation of aggregation propensity and formulation development for peptide drugs.
Understanding of peptide aggregation propensity is an important aspect in pharmaceutical development of peptide drugs. In this work, methodologies based on all-atom molecular dynamics (AA-MD) simulations and 1H NMR (in neat H2O) were evaluated as tools for identification and investigation of peptide aggregation. A series of structurally similar, pharmaceutically relevant peptides with known differences in aggregation behavior (D-Phe6-GnRH, ozarelix, cetrorelix, and degarelix) were investigated. The 1H NMR methodology was used to systematically investigate variations in aggregation with peptide concentration and time. Results show that 1H NMR can be used to detect the presence of coexisting classes of aggregates and the inclusion or exclusion of counterions in peptide aggregates. Interestingly, results suggest that the acetate counterions are included in aggregates of ozarelix and cetrorelix but not in aggregates of degarelix. The peptides investigated in AA-MD simulations (D-Phe6-GnRH, ozarelix, and cetrorelix) showed the same rank order of aggregation propensity as in the NMR experiments. The AA-MD simulations also provided molecular-level insights into aggregation dynamics, aggregation pathways, and the influence of different structural elements on peptide aggregation propensity and intermolecular interactions within the aggregates. Taken together, the findings from this study illustrate that 1H NMR and AA-MD simulations can be useful, complementary tools in early evaluation of aggregation propensity and formulation development for peptide drugs.
The
aggregation behavior of therapeutic peptides influences several
critical aspects of pharmaceutical development, such as the dosage
forms possible to develop, ease of manufacturing, formulation stability,
and patient safety and convenience.[1−5] Self-assembly is often an unwanted effect but can also be utilized
to alter the pharmacokinetics of peptide and protein drugs[6−8] and can improve the chemical and physical stability of a drug.[9] When peptides self-assemble, they can, similarly
to proteins, form various types of aggregates. The two most commonly
discussed aggregate types for therapeutic peptides are (1) amyloid-like
fibrils, where the peptides are folded into stacked β-sheets,
and (2) amorphous aggregates, that is, disordered structures.[5,8,10,11] Amyloid-like fibrils are known to be preceded by smaller aggregates,
for example, oligomers or fibril fragments (protofibrils or filaments),[5] and some peptides can form stable, well-defined
oligomers.[12] It is likely that transient
oligomers, which may involve just a few molecules, play a role in
the formation of larger aggregates. Transient oligomers may be particularly
relevant for small peptides, which often show high conformational
flexibility and a notably amphiphilic character. To obtain a good
understanding of the aggregation behavior of a peptide, methods that
can distinguish aggregates of different characters and sizes are of
importance.A wide range of approaches and techniques are applied
for the detection
of peptide aggregation and characterization of aggregates.[13,14] Large fibrils or amorphous aggregates (of μm scale or larger)
are detectable by optical microscopy or visual inspection, whereas
aggregates in an intermediate size range (nm to μm) can be identified
by, for instance, dynamic light scattering (DLS).[15] Fluorescence spectroscopy (intrinsic or extrinsic) can
be applied to investigate aggregates with distinct hydrophobic domains,[14,16] while oligomers or protofibrils of sufficient stability can be studied
by size exclusion chromatography[17,18] or analytical
ultracentrifugation.[13] Unfortunately, approaches
applied for investigating small peptide aggregates often involve changes
in solution conditions, risk of binding to column materials, and so
forth or require the addition of probe molecules, which may influence
peptide self-assembly both qualitatively and quantitatively and thereby
introduce a risk of inaccurate conclusions regarding the aggregation
behavior.In this work, 1H NMR spectroscopy and all-atom
molecular
dynamics (AA-MD) simulations were applied to investigate the aggregation
behavior of a series of structurally similar peptides with previously
known differences in aggregation propensity. 1H NMR spectroscopy
is a nondestructive technique with great potential for in situ detection
and investigation of peptide aggregation in solution, which does not
require the addition of external probe molecules. When a peptide molecule
takes part in an aggregate, it will experience changes in conformation,
local chemical environment, and mobility. These changes can influence
chemical shift, width, shape, and intensity of signals in an NMR spectrum.
Evaluation of changes and differences in the appearance of 1H NMR spectra with variation in sample composition and conditions
has been used for decades to investigate self-assembly of amphiphiles,[19−22] and similar approaches have been applied in the investigation of
peptide and protein aggregation in recent publications.[23−31]All-atom molecular dynamics (AA-MD) simulations give insights
into
molecular-level events on short (nano- to microsecond) time scales.
In particular, it is a useful tool for simulating interactions as
molecules coming into contact. AA-MD simulations have been used to
predict and reveal different aspects of aggregation behavior, for
example, to address monomer addition versus cluster–cluster
coalescence mechanisms,[32−34] interactions between proteins
and excipients,[35,36] and to investigate aggregation
pathways of the amyloid-β peptides—Aβ40 and Aβ42.[37]The experimental part of this work was
performed with four structurally
related decapeptides, which can be regarded as representative of a
series of candidate drug substances in the late discovery/early development
phase (see Figure ), D-Phe6-GnRH, ozarelix, cetrorelix, and degarelix (acetate
salts). These peptides are all analogues of gonadotropin-releasing
hormone (GnRH) with previously known differences in aggregation propensity.
One-dimensional 1H NMR in neat H2O was applied
to study aggregation of these peptides in a systematic manner. The
experiments were performed in regular water (H2O) rather
than deuterated water (D2O), which is commonly used in
NMR experiments, since the latter can have substantial influence on
the behavior of molecules in solution, for example, self-assembly
of amphiphiles,[38] the flexibility of folded
proteins,[39] and may also affect the aggregation
behavior of peptides. Furthermore, samples were prepared without buffer
or other added electrolytes to avoid possible, complicating salt effects.
Supportive NMR diffusometry measurements were performed on selected
samples (in D2O). AA-MD simulations were performed with
models of D-Phe6-GnRH (two different charge variants),
ozarelix, and cetrorelix.
Figure 1
Molecular structures and amino acid sequences
of the investigated
peptides.
Molecular structures and amino acid sequences
of the investigated
peptides.The aim of this work was to evaluate
the applicability of the developed 1H NMR methodology and
AA-MD simulations, individually and
in combination, in developability assessments and formulation development
of therapeutic peptides, and for investigation of solution behavior
and aggregation propensity.
Materials and Methods
Materials
D-Phe6-GnRH
acetate, ozarelix acetate, and cetrorelix acetate were prepared specifically
for this study by Red Glead Discovery, Lund, Sweden, and degarelix
acetate was a gift from Ferring Pharmaceuticals A/S. According to
the respective providers, the free base contents of D-Phe6-GnRH, ozarelix, cetrorelix, and degarelix were 88, 95, 96, and 87%,
respectively, whereas the molar ratios of acetate/acetic acid to peptide
were 1.7, 1.0, 1.0, and 2.5. Aqueous solutions were prepared with
water purified using a Milli-Q system. D2O (99.8%) used
in the NMR diffusion experiments was obtained from Armar Isotopes,
Germany.
Sample Preparation, Handling, and Characterization
by Visual Inspection
1H NMR experiments were performed
at peptide concentrations of 0.1, 0.5, 1, 2, 5, and 10 mM in 100%
H2O. Peptide solutions were prepared in glass vials without
pH adjustments, as the addition of concentrated acid or base results
in local pH variations that might induce aggregation. Diffusion NMR
experiments were performed at peptide concentrations of 3 and 10 mM
in 100% D2O. Thus, the diffusion NMR results may not be
perfectly representative of the situation in the samples in H2O, but general conclusions can still be drawn.The samples
were gently agitated, by manual swirling, until the solution appeared
visually homogeneous and 450 μL of each sample was transferred
to disposable 5 mm NMR tubes (Type 5TA 178 mm from Teknolab Sorbent,
Sweden). Aliquots were pipetted slowly to reduce the risk of possible
shear-induced aggregation. The time between sample preparation and
the start of the NMR measurement was around 15 min. On selected samples,
the approximate pH was assessed with pH indicator strips (Scharlau,
pH 2.0–9.0, TP0209000S) after aliquots for the NMR samples
were taken out.The NMR tubes containing samples were visually
inspected in a light
box and compared to an NMR tube containing pure water to simplify
identification of visually detectable aggregates.
1H NMR—Instruments and Experimental
Setup
NMR experiments were performed at 25 °C on either
a Varian Unity Inova 500 MHz spectrometer equipped with a Z-spec DBG500-5EF
5 mm dual broadband gradient probe or a Bruker AVANCE III HD 500 MHz
spectrometer equipped with a BBO probe, Bruker SMART probe. Spectra
were recorded with an excitation sculpting sequence for solvent suppression.[40] Experiments on the Varian spectrometer were
run as soon as possible after sample preparation (typically within
15 min), after 24 h, and after 1 week with an excitation pulse width
of 11.8 μs (corresponding to a 90° pulse), a spectral width
of 8 kHz, an acquisition time of 2.048 s, and a recycle delay of 4.0
s. On the Varian, 300 scans were used on samples of 0.1–1 mM
and 64 on 1–10 mM (1 mM was measured using both settings to
bridge the concentration series and ensure comparability), which gave
adequate signal for unaggregated samples. In the case of aggregation,
reduction in signal strength is expected.Experiments on the
Bruker spectrometer were run as soon as possible after sample preparation
(typically within 15 min), after 2 h, and after 48 h, with an excitation
pulse width of 9.5 μs (corresponding to a 90° pulse), a
spectral width of 6.6 kHz, and the collection of 512 scans. The acquisition
time and recycle delay were kept the same within each concentration
series but varied between the peptides to allow for appropriate decay
of the FID. The combined settings for acquisition time and recycle
delay were either 1.0 and 2.0 s or 2.9 and 0.1 s, respectively. To
gain insights into possible changes in spectral appearance on a short
time scale, two experiments with 4 scans were performed 10 min apart
in connection to the initial measurement, and an additional 4 scan
measurement was performed at all consecutive time points. Between
NMR experiments, samples were left in an upright position on a gently
rocking cradle at room temperature.As no deuterated solvent
was included in the samples, the 1H NMR experiments were
performed without the application of
a field-frequency lock. However, since the time scale of the experiments
was relatively short and the spectrometers used did not show a notable
drift, the omission of field-frequency lock did not have an appreciable
impact on the quality of the recorded spectra. Shimming was performed
by gradient shimming on the solvent (H2O) signal.
1H NMR—Data Treatment
Each spectrum
was phase- and baseline-corrected prior to integration
in an ACD/Spectrus Processor (version 2021.1.1, Advanced Chemistry
Development, Inc., Toronto, On, Canada, www.acdlabs.com 2021). The ppm
scale was referenced to the rightmost peak from the leucine or nor-leucine
side chains, for which the chemical shift was set to 0.7 ppm.The absolute integral values (IntC), at each investigated
concentration, for signals arising from the methyl groups of leucine
(6H; for D-Phe6-GnRH, cetrorelix, and degarelix) or nor-leucine
(3H; for ozarelix) were determined. This signal is a doublet of doublets
or a multiplet at 0.7–0.8 ppm (Figure ) and was selected as it did not show obvious
overlap with other signals. From IntC, the normalized absolute
integral value, NAI, was calculated as described in eq , where IntC and Cmin are the absolute integral value
and the concentration for the lowest peptide concentration studied
(0.1 mM), respectively. Additionally, IntC of the signal
from the acetate counterion (a singlet) were determined for all peptides.
For ozarelix and cetrorelix, there was an overlap of the acetate signal
and the signal from the N-terminal acetyl group (also a singlet; Figure ); for these peptides,
IntC represents the combined integral area of both these
peaks. Collected data were further processed to obtain a shape index,
SI (defined in eq ),
and the concentration normalized absolute integral value, CNAI (defined
in eq ). The SI, based
on the intensity to integral ratio, decreases with peak width, while
CNAI diverts from unity as the signal disappears due to extensive
broadening.Imax is the maximum
absolute peak intensity value and C is the molar
concentration.
Figure 2
Partial 1H NMR spectra displaying the variation
in spectral
appearance with concentration. For a–d, the same intensity
scale is used for all spectra to show changes in intensity. In e–h,
spectra were individually scaled to yield similar intensity for the
leucine/nor-leucine methyl peaks in all spectra.
Figure 3
Partial 1H NMR spectra showing the development in appearance
and chemical shift of the signals from the acetate counterion and
the N-terminal acetyl group (see Section S3.3). The spectra in a–c are scaled as in Figure e–g, whereas degarelix spectra are
normalized to concentration.
Partial 1H NMR spectra displaying the variation
in spectral
appearance with concentration. For a–d, the same intensity
scale is used for all spectra to show changes in intensity. In e–h,
spectra were individually scaled to yield similar intensity for the
leucine/nor-leucine methyl peaks in all spectra.Partial 1H NMR spectra showing the development in appearance
and chemical shift of the signals from the acetate counterion and
the N-terminal acetyl group (see Section S3.3). The spectra in a–c are scaled as in Figure e–g, whereas degarelix spectra are
normalized to concentration.
NMR Diffusometry
NMR diffusion experiments
were performed at 25 °C on a Bruker AVII-200 spectrometer equipped
with a Bruker DIFF-25 gradient probe and a Bruker GREAT 1/40 gradient
amplifier using a pulsed field gradient stimulated echo (PFG-STE)
sequence. Additional details regarding the diffusion measurements,
including relevant theory related to the interpretation of the results,
are presented in Section S4.
AA-MD Simulations
Construction of
D-Phe6-GnRH, cetrorelix, and ozarelix topologies was performed
using the Charmm36 force field,[41,42] with the non-natural
residues in the peptides represented by parameters from the SwissSidechain
database[43] and incorporated into the peptides
using the PyMol plugin provided on the SwissSidechain website. Degarelix
was not included in the simulations due to parameterization challenges
and because of the indications from NMR of a more complex aggregation
behavior. In each AA-MD simulation, 20 peptides were placed in a cubic
box with a side length of 15 nm, which gives a peptide concentration
in the AA-MD simulations similar to the highest concentration used
in the NMR experiments (i.e., 10 mM) and a setup with a good balance
between simulation box size and computational efficiency. Simulations
of cetrorelix and ozarelix were performed on peptide molecules with
a total charge of +1 (on the arginine residue), whereas simulations
of D-Phe6-GnRH were performed under two different conditions,
with the histidine side chain being either neutral or charged (which
gives total peptide charges of +1 or +2, respectively), resulting
in a total of four simulated systems. Three independent simulations
were performed for each system with the peptides initially placed
randomly in the simulation box. The numbers of aggregates and free
peptide monomers were calculated using an in-house Python code, with
two peptide molecules considered to be in the same aggregate if any
of their constituent atoms were found within a cutoff distance of
0.5 nm.[32] The simulations were performed
with chloride as the counterion, while the NMR experiments were performed
on acetate salts of the respective peptides. The interactions between
cetrorelix and chloride or acetate ions were compared by calculating
the ion-peptide radial distribution functions and minor differences
were found. While the choice of counterion can have an impact on long-term
aggregation behavior, the observed differences in peptide–counterion
interactions with the different counterions are not expected to be
critical for the time scales and aggregation sizes studied. Additional
details regarding the simulation setup and analysis protocols are
presented in Section S6.
Results and Discussion
Macroscopic Behavior of
Samples
Most
samples, including all samples of D-Phe6-GnRH and degarelix,
were visually clear over the investigated time span. Freshly prepared
samples of cetrorelix at concentrations of 2 mM and above and ozarelix
at concentrations of 5 mM and above showed a slight turbidity, which
remained at all following time points of inspection (example photographs
are shown in Figure S1). A faint turbidity
also appeared within 2 h for samples of 1 mM cetrorelix and 2 mM ozarelix.
The slight turbidity suggests the presence of aggregates or particles
with sizes of a few hundred nanometers or larger. Furthermore, a slight
increase in viscosity (identifiable by visual observation) with increasing
concentration was noticed for all investigated peptides except for
D-Phe6-GnRH.The peptide samples showed pH in the
range of ∼5.5 to ∼8.5, varying with peptide type, concentration,
and time. At these pH values, all the investigated peptides residing
in solution are expected to carry an average charge of +1 or somewhat
higher. Additional details regarding sample pH and peptide charge
are presented in Section S2.
NMR Results and Implications Thereof
This section begins
with a brief presentation of how peptide aggregation
is expected to influence 1H NMR spectra, followed by an
overview of representative NMR data and a discussion on the significance
of the results, with respect to the aggregation behavior of each peptide.
Consequences of Aggregation on Appearance
of 1H NMR Spectra
When a molecule, for example,
a peptide, takes part in an aggregate, it is expected to experience
changes in conformation, local chemical environment, and mobility
compared to the situation when it is present as a monomer. The chemical
shift (i.e., the position in the spectrum) of an NMR signal is influenced
by molecular conformation and local chemical environment. On the other
hand, the width and shape of NMR signals are influenced by molecular
mobility and rate of reorientation (as a consequence of the influence
of mobility on the spin–spin relaxation time, T2) and thereby by aggregate size. Significant signal broadening
is typically observed with aggregates of sizes of tens to hundreds
of nm, but line shape is also influenced by, for example, aggregate
rigidity and geometry. Molecules residing in large aggregates (hundreds
of nm or larger) become practically undetectable in liquid-state NMR
(see Section S3.1 for additional comments
on line width, T2, and aggregate size).
Taken together, systematic evaluation of variations in the appearance
of NMR spectra with concentration and time can provide insights into
oligomerization and aggregation of peptides.
Variation
among 1H NMR Spectra
with Concentration and Time
Partial 1H NMR spectra
of samples of between 0.1 and 10 mM of the four investigated peptides
are shown in Figure (signals from aliphatic moieties of the peptide molecules) and Figure (signals from acetate
counterion and the N-terminal acetyl group). Additional details of
the spectra of all samples and interpretations of these are presented
in Figure S3.For most samples, signal
broadening (when observed) occurred to a similar degree for all signals
in the respective NMR spectra and the relative intensities of signals
within each spectrum were practically unchanged. Thus, the variation
in intensity and shape of a single, well-separated signal is largely
representative of the whole spectrum (the main exception is the group
of broad signals between 1.2 and 1.6 ppm observed for samples of degarelix
at 1 mM or higher, see Figure h and discussion below). The variation of integrals and intensities
of such a signal with concentration and time can be used for straightforward
comparison of key trends in the NMR results. Figure a–d is derived from the signals of
the methyl groups of amino acid residue 7 (leucine or nor-leucine). Figure a,b shows the variation
in NAI (defined in eq. ) with concentration. In this representation, deviation from a linear
increase in NAI suggests aggregation. Figure c shows the variation in SI (as defined in eq. ) with concentration,
where lower SI represents broader signals. Figure d presents the CNAI (defined in eq ) at different concentrations and
time points. Here, a decrease in CNAI with concentration indicates
onset of aggregation or an increase in the aggregated fraction (if
aggregates are present already at the lowest investigated concentration). Figure e shows the corresponding
CNAI plot for the signals from the acetate counterion (or in the cases
where signals from acetate and N-terminal acetyl group are overlapping,
a sum of both integrals).
Figure 4
Different representations of the NMR data with
concentration. (a–d)
Data for the leucine or nor-leucine methyl groups (appearing at 0.7–0.8
ppm) and (e) data for the counterion acetate (appearing at 1.7–1.9
ppm). Panels (a,b) display NAI (see eq ) for spectra recorded after 48 h. The SI (linked to
peak broadening) for spectra recorded after 24 h is displayed in panel
c (see eq ). Panels
(d,e) display CNAI (see eq ).
Different representations of the NMR data with
concentration. (a–d)
Data for the leucine or nor-leucine methyl groups (appearing at 0.7–0.8
ppm) and (e) data for the counterion acetate (appearing at 1.7–1.9
ppm). Panels (a,b) display NAI (see eq ) for spectra recorded after 48 h. The SI (linked to
peak broadening) for spectra recorded after 24 h is displayed in panel
c (see eq ). Panels
(d,e) display CNAI (see eq ).Most samples showed no notable
changes in CNAI and line shape over
the investigated time span. The main exceptions were observed for
cetrorelix and ozarelix at 1 and 2 mM, which showed substantial decrease
in CNAI over time (Figure d). Additional comments on changes over time are found in Section S3.4.
D-Phe6-GnRH
The spectra
of D-Phe6-GnRH show an essentially linear increase in absolute
integral with increasing concentration (Figure a,b,d) and a practically unchanged general
appearance, with narrow signals throughout the investigated concentration
and time ranges (Figures e and 4c). Furthermore, the behavior
of the acetate counterion signal parallels that of the signals from
the peptide itself (Figures a and 4e). These observations suggest
that D-Phe6-GnRH is predominantly present as individually
dissolved monomers. The conclusion that self-assembly of D-Phe6-GnRH is limited (or absent) is further supported by results
from NMR diffusion measurements. The samples of 3 or 10 mM D-Phe6-GnRH (in D2O) both showed very similar self-diffusion
coefficients, consistent with a majority (or all) of the peptide being
present as individual molecules in solution in the whole investigated
concentration range (presence of a minor fraction of transient oligomers
cannot be excluded based on the collected NMR diffusion results, see Section S4 for additional comments).
Ozarelix and Cetrorelix
Ozarelix
and cetrorelix both show maxima in intensity and absolute integrals
between 0.5 and 2 mM (Figures b,c and 4a,b,d), as well as a similar
degree of progressive, spectrum-wide broadening between 2 and 10 mM
(Figures f,g and 4c). Peak broadening and loss of signal is attributable
to aggregation, and based on the plots of CNAI and SI versus concentration,
the NMR results demonstrate the occurrence of substantial aggregation
from at least ∼0.1 mM and above for cetrorelix and above ∼1
mM for ozarelix (Figure c,d). The fact that ozarelix shows a CNAI of ∼1 up to the
1 mM data point suggest that it is predominantly present as monomers
and/or resides in transient oligomers up to this concentration. For
cetrorelix, where the CNAI decreases with concentration immediately
above 0.1 mM (as well as with time), large aggregates may also be
present at the lowest concentration investigated in this study (because
of normalization to the integral for the 0.1 mM sample) and the concentration
for onset of aggregation can thus not be determined.For both
ozarelix and cetrorelix, signals from the acetate counterion (a singlet)
show considerable overlap with the signal from the N-terminal acetyl
group (also a singlet; Figure b,c and additional comments in Section S3.3). However, it is still clear that the signals from acetate
show broadening and signal loss similar to what is observed for the
peptide itself (Figures b,c and 4e). This shows that the acetate counterions
are predominantly included in the peptide aggregates formed.The onset of effective signal loss at lower concentrations for
cetrorelix than ozarelix (Figure d,e) is consistent with the observation of visually
detectable turbidity at lower concentration for cetrorelix than ozarelix
(at 2 and 5 mM, respectively, at the initial time point). Furthermore,
the reductions in absolute integral over time for the samples of 1
mM cetrorelix or 2 mM ozarelix (Figure d) are correlated with the appearance of turbidity.
However, the NMR results clearly show substantial aggregation at concentrations
well below the concentrations where aggregation is detectable by turbidity.
Evaluation of ozarelix and cetrorelix samples in NMR diffusion measurements
(at 3 and 10 mM in D2O) was not possible due to the presence
of large aggregates, that is, appropriate signal was not observed,
see Section S4. The absence, at higher
concentrations, of sharp signals from peptide and counterions in solution
suggests a very low peptide solubility, that is, a low fraction of
nonaggregated peptide and/or fast exchange between individually dissolved
monomers or oligomers and molecule aggregates (although the latter
is considered less likely for a peptide with known tendencies to form
β-sheets).[44,45]
Degarelix
Overall, the 1H NMR spectra of degarelix show a similar
development with concentration
as the spectra of ozarelix and cetrorelix. However, the results for
degarelix differ in two important respects: (I) in addition to the
general signal broadening with increasing concentration, a distinct
group of broad peaks appear in the range between 1.2 and 1.6 ppm at
concentrations of 1 mM or higher (Figure h), and (II) the absolute integral of the
acetate counterion signal, which remains narrow over the investigated
concentration range, increases linearly with the nominal peptide concentration
(Figures d and 4e).The relative intensity of the group of
peaks between 1.2 and 1.6 ppm increases with concentration (Figure h). Furthermore,
the signals in this range appear to be distinctly different from the
other signals in the same spectra (with respect to chemical shift
and line shape) and are practically invariant in shape at all concentrations
where they are observed. These findings suggest that they arise from
aggregates involving a fraction of peptide distinct from that resulting
in practically complete signal loss, which show slow exchange with
monomers and/or small transient oligomers in solution. This is also
supported by results from the NMR diffusometry experiments (at 3 and
10 mM in D2O), which suggest the presence of distinct fractions
of intermediately sized aggregates ranging from single molecules and/or
small oligomers up to aggregates of at least tens of molecules (see Section S4 for additional comments).The
fact that the signal from the acetate counterion parallels
the nominal peptide concentration reveals that the counterions largely
remain in solution when degarelix self-assemble into larger structures.
In turn, this suggests that degarelix resides in aggregates predominantly
in its uncharged form. The idea that the acetate ions are largely
free in solution is supported by the NMR diffusion measurements, which
show that the self-diffusion coefficient of the acetate ions in the
degarelix samples is similar to that recorded for acetate in the D-Phe6-GnRH samples.To summarize, degarelix appears to reside
in at least three categories
of aggregates: free monomers/small oligomers, intermediately sized
aggregates (which give rise to the group of broad NMR signals between
1.2 and 1.6 ppm), and large aggregates (which are largely undetected
in the NMR spectra). The large aggregates in degarelix samples do
not result in visually detectable turbidity. This indicates that the
aggregates formed differ in size and/or structure from those of ozarelix
and cetrorelix.
Molecular Aggregation Pathways
The aggregation pathways,
as observed in the simulations, are shown
in Figure . It can
be seen in snapshots of the peptides after 500 ns (Figure , top) and from aggregation
transition networks (Figure , bottom) that both cetrorelix and ozarelix monomers coalesce
over time into aggregates that include all 20 peptide molecules present
in the simulation box. For D-Phe6-GnRH, the aggregate size
is much smaller, and the maximum aggregate size found in the simulations
was n = 15 and n = 8 with uncharged
(peptide net charge of +1) and charged histidine (peptide net charge
of +2), respectively.
Figure 5
Top: Simulation snapshots (at 500 ns) of cetrorelix, ozarelix,
and D-Phe6-GnRH. Peptide backbone and side chain atoms
are colored green and blue, respectively. Bottom: Peptide aggregation
transition networks. Numbers on each node represent the number of
molecules in an aggregate, and the size of the nodes is proportional
to the number of aggregates with that particular size. Arrow thickness
is proportional to the number of transitions between that pair of
nodes.
Top: Simulation snapshots (at 500 ns) of cetrorelix, ozarelix,
and D-Phe6-GnRH. Peptide backbone and side chain atoms
are colored green and blue, respectively. Bottom: Peptide aggregation
transition networks. Numbers on each node represent the number of
molecules in an aggregate, and the size of the nodes is proportional
to the number of aggregates with that particular size. Arrow thickness
is proportional to the number of transitions between that pair of
nodes.It is evident for all the studied
peptides that aggregation mainly
starts with monomers forming dimers and trimers. These then grow either
by monomer addition or by being associated with other small aggregates,
resulting in the formation of larger aggregates. For cetrorelix and
ozarelix, these aggregates then coalesce, eventually leading to the
formation of aggregates containing all 20 peptide molecules. In the
simulations of D-Phe6-GnRH(His+), dimers were seen to dissociate
following their formation, and there was practically no coalescence
of medium-sized aggregates.
Molecular
Aggregation Dynamics
When evaluating the simulation data,
the number of peptide molecules
needed to define an aggregate can be set at different levels, by varying
the aggregation cutoff size. For instance, with a cutoff size n = 2, only individual peptide monomers are considered nonaggregated,
compared to n = 10, where peptide monomers and oligomers
consisting of less than 10 peptide molecules are considered nonaggregated.
Evaluation of different cutoff values allows us to further investigate
the dynamics of the peptide aggregation process. The percentages of
nonaggregated peptide molecules were calculated by considering four
aggregate cutoff sizes (n = 2, 4, 6, and 10) as shown
in Figure . The fraction
of nonaggregated peptides for cetrorelix and ozarelix is greatly reduced
during the simulation (500 ns) for all cutoff sizes. For D-Phe6-GnRH (both uncharged histidine and His+), the nonaggregated
fraction, at the end of the simulation, increases with aggregate cutoff
size. With n = 2, the number of free monomers for
cetrorelix and ozarelix is rapidly reduced, reflecting an initial
period where the system is dominated by the diffusion of peptide monomers.
This phenomenon has been observed in other simulation studies of peptide
aggregation.[34,46,47] Hence, there is a very low percentage of free monomers for much
of the simulation, eventually reaching zero at 400 ns. For D-Phe6-GnRH with uncharged histidine, the fraction of free monomers
is similarly reduced early in the simulations but then stabilizes
at around 20% of free monomer, while D-Phe6-GnRH with charged
histidine (His+) stabilizes at about 40%. Thus, the presence of the
charged histidine increases the percentage of free monomers for D-Phe6-GnRH compared to the D-Phe6-GnRH with uncharged
histidine. At higher cutoffs, cetrorelix and ozarelix showed a similar
behavior, and even with n = 10, the amount of nonaggregated
peptide was low at 500 ns. In contrast, at n = 10,
all D-Phe6-GnRH(His+) molecules are present either as monomers
or as smaller oligomers (in Figure , the maximum aggregate size is n =
8). The formation of medium-sized aggregates (at least up to n = 6 molecules) appears to be a more rapid process for
cetrorelix and ozarelix than for D-Phe6-GnRH.
Figure 6
Evolution of
the percentage of nonaggregated peptides during AA-MD
simulations at aggregate cutoff sizes n = 2, 4, 6,
and 10, shown in panels (a–d), respectively.
Evolution of
the percentage of nonaggregated peptides during AA-MD
simulations at aggregate cutoff sizes n = 2, 4, 6,
and 10, shown in panels (a–d), respectively.To give additional insights into aggregation dynamics, peptide–peptide
binding and unbinding events were quantified from the simulation data.
After about 50 ns, binding or unbinding rarely occurred for cetrorelix
and ozarelix (Figure a,b). This is consistent with rapid onset of aggregation and in contrast
to the result for both D-Phe6-GnRH configurations (Figure c,d). Assemblies
of both D-Phe6-GnRH configurations, particularly D-Phe6-GnRH(His+), are very dynamic, with binding or unbinding occurring
at the same level throughout most of the simulation, indicating that
oligomers are formed and dissociated throughout the simulation.
Figure 7
Number of binding
and unbinding events during the simulation period.
Number of binding
and unbinding events during the simulation period.The collision acceptance probability, CAP, was calculated
from
the number of binding and unbinding events according to eq S5. A CAP value close to one is taken to indicate
an aggregation prone peptide. While simulations are not directly comparable
with experiments, due to the difficulties of tracking single-molecule
binding and unbinding experimentally, CAP values provide an intuitive
way to rank peptides in terms of aggregation propensity and have previously
been used for peptides both experimentally and in simulations.[34] CAP values are also independent of the time
period for which a peptide monomer stays bound or unbound, in contrast
to association and disassociation constants. Calculated CAP values
for the simulated peptides are found in Table S4. Based on these values, the following rank order of aggregation
propensity can be proposed: cetrorelix > ozarelix > D-Phe6-GnRH (uncharged histidine) > D-Phe6-GnRH(His+).
Molecular Interactions within the Aggregates
Peptide–peptide contacts, including hydrogen-binding patterns,
were analyzed to gain further molecular insights into possible predominant
peptide–peptide interactions within the aggregates. The results
(Figure ) indicate
that for both cetrorelix and ozarelix, residues near the N-terminal
(N-acetyl-d-(β-naphthyl)alanine (D-2Nal), d-(4-chloro)phenylalanine (D-4Cpa), d-(2-pyridyl)alanine
(D-3Pal), and tyrosine (Tyr) or N-methyl tyrosine
(N-Tyr) play a dominant role among the intermolecular contacts. This
seems to contribute to differentiating the overall aggregation propensity
of these peptides. In contrast, although D-Phe6-GnRH (neutral
histidine and His+) shows fewer peptide–peptide interactions,
overall, peptide–peptide interactions are dominated by the
hydrophobic residues (tryptophan, tyrosine, and phenylalanine). Electrostatic
peptide–peptide repulsion between charged histidine side chains
is also evident for D-Phe6-GnRH(His+).
Figure 8
Average interpeptide
residue–residue contact frequencies,
with contacts normalized by the number of cetrorelix contacts.
Average interpeptide
residue–residue contact frequencies,
with contacts normalized by the number of cetrorelix contacts.Hydrogen bonds are formed between peptide molecules
and between
peptide molecules and water (Figure S7).
The least aggregation-prone peptide [D-Phe6-GnRH(His+)]
forms the largest number of peptide–water hydrogen bonds, while
cetrorelix has the highest number of peptide–peptide hydrogen
bonds. The simulations indicate intermolecular hydrogen bonds particularly
for the tyrosine moiety in cetrorelix (Figure S8).Finally, to complement understanding of the molecular
interactions
that might cause the variations in aggregation behavior among the
peptides, the exposure of the peptide amino acids to the solvent was
characterized by assessing the hydrophobic solvent-accessible surface
area (hSASA, summarized in Table S5). Again,
a distinction between cetrorelix/ozarelix and D-Phe6-GnRH
can be observed, already for monomers and dimers. The average hSASA
for cetrorelix and ozarelix is similar, while it is roughly 20% lower
for D-Phe6-GnRH. The relatively lower hSASA values of D-Phe6-GnRH might thus in part explain the reduced aggregation tendency
of this peptide. The hSASA value does not allow for a clear distinction
between the two D-Phe6-GnRH systems; the values are within
the standard deviation of each other, which presumably reflects the
delicate balance between electrostatics, hydrophobic interactions,
and conformational flexibility.
Information
on Peptide Aggregation Provided
by the Applied Methodologies
Aggregation Propensity
Rank Order
The peptide aggregation propensity rank order
can be assessed with
both the NMR and AA-MD methodologies evaluated in this work. The peptides
investigated by AA-MD simulations were shown to give the same rank
order with respect to the general aggregation propensity as in NMR;
cetrorelix > ozarelix > D-Phe6-GnRH. This rank order
is
also consistent with results from a previous fluorescence spectroscopy
investigation of the same three peptides (in 10 mM ammonium acetate
buffer at pH 7.0). The fluorescence study showed critical peptide
aggregation concentrations (CAC) of 0.04 and 0.17 mg/mL (∼0.03
and ∼0.1 mM) for cetrorelix and ozarelix, respectively, whereas
no distinct aggregation concentration was identified for D-Phe6-GnRH at concentrations up to 10 mg/mL (8 mM).[16] In the current NMR study, peptide concentrations
above the peptide CAC (as determined with fluorescence) were investigated;
still, the same peptide aggregation rank order was observed. The NMR
results suggest that although there appears to be notable differences
in the character of the aggregates formed, the general aggregation
propensity of degarelix is similar to that of cetrorelix.The
predicted peptide aggregation rank order, among a series of related
peptides, can be described by comparison of single numbers through
calculation of the CAP from the number of binding and unbinding events
in the AA-MD simulations. The peptide aggregation rank order from
NMR is visualized through the CNAI expressed as a function of peptide
concentration (Figure d).
Coexistence of Different Aggregate Types
The NMR results on degarelix illustrate that it can be possible
to identify the presence of coexisting aggregate types. For different
aggregates to give distinct signals, the rate of exchange of peptide
molecules between aggregates of different types needs to be relatively
slow; the exact time scale depends on differences in chemical shifts
and/or line shapes of signals in the spectra of the individual aggregate
types.In some instances, the fact that large aggregates may
not give rise to a detectable NMR signal can be an obvious drawback.
For instance, the presence of a small fraction of large aggregates
can easily remain undetected in an NMR experiment. On the other hand,
this also means that NMR experiments can allow for detection of variations
or changes (or lack thereof) in a fraction of smaller aggregates that,
in the presence of coexisting large aggregates, can be difficult to
capture using alternative techniques (e.g., by DLS, for which results
are weighted by larger particles). Results from a previous study,
where 1H NMR was evaluated as a potential tool for quality
control of the lyophilized peptide drug product, exemplify such a
situation. For a series of samples of FIRMAGON (degarelix) drug product
reconstituted in D2O, NMR spectra remained practically
unchanged over time while an increase in the fraction of large aggregates
was detected by DLS.[30]The fact that
signal from a small fraction of large aggregates
is effectively filtered out in 1H NMR can be useful in
developability assessment of drug substance batches containing significant
levels of impurities (which is commonly the case for early development
batches). If impurities show higher aggregation propensity than the
main component, methods sensitive to the presence of a small fraction
of large aggregates (such as DLS) may result in inaccurate conclusions
regarding aggregation propensity.
Influence
of Different Structural Elements
on Peptide Aggregation Propensity
The AA-MD simulations provide
information regarding the influence of different structural elements
on peptide aggregation propensity. A key conclusion from the contact
map in Figure is
that close interactions among side chains of aromatic amino acid residues
are important points of interaction for all peptides investigated.
Based on the contact maps, the main point of attractive interaction
among the peptide molecules is the N-acetyl-d-(β-naphthyl)alanine (D-2Nal) residue that is present at the
N-terminal in ozarelix, cetrorelix, and degarelix, which all show
extensive aggregation at low concentration, but is absent in the structure
of D-Phe6-GnRH. This finding is consistent with a general
notion that hydrophobic interaction is a key driver in peptide aggregation
and is specifically supported by results from intrinsic fluorescence
experiments, where fluorescence shifts were observed for D-2Nal as
aggregation was identified.[16] It is expected
that the position of hydrophobic amino acids in the peptide sequence
is a factor of importance for the degree of hydrophobic interactions
among peptide molecules.[8,48,49] A location close to an end of the peptide chain can likely promote
attractive interaction (less steric hindrance and higher exposure
to surrounding), whereas proximity to a charged amino acid can hamper
close interaction (opposing electrostatic repulsion).The importance
of certain intermolecular hydrogen bonds suggested by the simulations,
particularly for the tyrosine residue in cetrorelix (Figure S8), also correlates with findings from the previous
fluorescence study.[16]
Fate of Counterions in Peptide Aggregation
The different
results on the acetate counterions for the three
aggregating peptides show that 1H NMR can be applied to
distinguish inclusion (as for ozarelix and cetrorelix) from exclusion
(as for degarelix) of organic counterions in peptide aggregates formed.
Inclusion or exclusion of counterions in peptide aggregates can be
difficult to capture with other techniques and is a, to our knowledge,
rarely discussed but potentially important aspect of peptide aggregation.
The fate of the counterion on aggregation of a certain peptide is
potentially dependent on the type of counterion (specific ion effects)
and on the solution conditions (pH, type(s), and concentration(s)
of cosolutes) and may be associated with fundamental differences in
the structure and other properties of the aggregates formed. 1H NMR can thus be useful in counterion-screening studies aiming
to tune the properties of a peptide in aqueous formulation.
Effect of Solution Conditions on Peptide
Aggregation
The herein-used NMR methodology is readily applicable
in investigations on the impact of solution conditions (type and concentration
of excipients, pH, etc.) on peptide aggregation and can thereby be
valuable in, for example, formulation screening studies. The possibility
to use 1H NMR for evaluating the impact of excipients on
peptide aggregation is exemplified by results from the aforementioned
study,[30] where it was shown that buffer
or background salt strongly enhance aggregation of degarelix (observed
as reduction in total detectable signal and a decrease in the fraction
of sharp signals). It should be kept in mind that organic cosolutes
give NMR signals that may be superimposed on certain signals from
the peptide. However, study of variations in general features of the
peptide spectrum, such as variation in line broadening or the intensity
of the detectable signal in the presence of organic solutes, can often
still be possible without major problems.The impact of solution
conditions on aggregation can to some extent be investigated also
in simulations. Effects of varying pH can be addressed by performing
simulations on models with different protonation states. In the simulations
of D-Phe6-GnRH, the aggregation propensity was found to
be lower with charged histidine (i.e., with a total peptide charge
of +2) than with uncharged histidine (total peptide charge of +1),
which is consistent with an expected importance of electrostatic repulsion
for a reduction in aggregation propensity. This result is also well
in line with consequences of variation in charge observed experimentally
for triptorelin, another GnRH analogue with an amino acid sequence
similar to that of D-Phe6-GnRH.[50] However, irrespective of the aggregation state, D-Phe6-GnRH shows lower aggregation propensity than both ozarelix and cetrorelix,
which both carry a total charge of +1 in the simulations, illustrating
the importance of the specific amino acid sequence for controlling
aggregation propensity.
Variation in the Extent
of Aggregation over
Time
The NMR results on ozarelix and cetrorelix show that 1H NMR can be applied to study variations in the extent of
aggregation over time. This aspect is also exemplified by previously
published results where variations in the degree of aggregation of
degarelix over time were identified in the presence of buffer or background
salt,[30] which illustrates a useful application
in excipient screening studies.
Application
of NMR and AA-MD Simulation in
Developability Assessments and Early Formulation Development of Therapeutic
Peptide Formulations
At early stages of development, the
amount of peptide available is usually very limited and nondestructive
methods, such as NMR, and reliable simulation tools for predicting
aggregation propensity are desirable.Results presented above
demonstrate that the herein-developed NMR methodology, which can be
applied using conventional experimental procedures on standard 1H NMR spectrometers, is useful for detection of peptide aggregation
and differentiation of structurally similar peptides with respect
to aggregation propensity and behavior. For NMR studies in general,
the required amount of the sample and the experimental time depend
on several aspects, including the peptide concentration range of interest,
the molecular structure of the peptide (which influences, e.g., the
signal splitting patterns, the degree of signal overlap, and the number
of protons contributing to a certain signal), and the sensitivity
of the spectrometer used. Using lower-volume NMR tubes, lower sample
amount is sufficient. However, a reduction in sample amount will typically
increase the required experimental time and thereby limit the temporal
resolution for investigation of peptide aggregation. NMR is typically
not suitable for monitoring of fast aggregation processes, as the
required experimental time is usually minutes or longer but is well-suited
for the investigation of longer-term physical stability.In
contrast to more advanced NMR techniques,[51] the herein-applied 1H NMR experiments cannot
reveal details regarding aggregate structures but can, as is illustrated
by the results presented above, readily identify the occurrence of
extensive aggregation (by substantial line broadening or loss of signal)
and qualitative differences in the aggregation behavior among peptides.
Plots as those presented in Figure allow a straightforward comparison of 1H NMR spectra for a series of peptides and evaluation of differences
in their aggregation behavior. Furthermore, the results from this
study illustrate that 1H NMR can be used to study aspects
of peptide aggregation that can be difficult to capture using alternative
techniques, such as the presence of different populations of aggregates
(e.g., the intermediate aggregates observed for degarelix) and the
inclusion or exclusion of counterions in aggregates. Taken together,
the present work shows that 1H NMR in neat H2O constitutes a powerful tool for the investigation and classification
of peptide aggregation.In silico methods have become a growingly
important tool in the
drug discovery phase of design of new drug substances.[52] There is a strong interest in obtaining similar
tools for the drug development phase. The results from this work show
that AA-MD simulations can give important information for early development
of peptide drugs. It was found that there was a good correlation between
the experimental and AA-MD simulation results. A drawback for AA-MD
simulations is that setup and execution can be slow, limiting the
time and length scales that can be accessed in studies. This can in
part be alleviated by enhanced sampling techniques but will be particularly
obvious when low concentrations of molecules are needed, in which
case a balance must be struck between the size of the simulation box
and the number of included molecules. This makes it difficult to study,
for example, low concentrations of peptides. Increasing computing
power and continued development of algorithms will improve this.An advantage of simulations is that these can give indications
of the fast dynamics in the system. In this work, this was seen in
both the peptide aggregation transition networks and the frequency
of binding and unbinding events. It could, for instance, be shown
that there was a clear difference in the numbers of binding and unbinding
events between the peptides that have been shown experimentally to
have a large propensity to aggregate and those that have low aggregation
propensity. Another strength of simulations is that they give detailed
molecular information about the aggregates, allowing for hypotheses
about specific interactions in and between the peptide molecules,
in this work illustrated by the fact that it was possible to identify
the amino acids that are most likely involved in interactions within
the aggregates. Another example of how simulations can provide information
on the molecular level is the study of the charged/uncharged histidine
residue that provided information on possible pH effects on the peptide.
Taken together, results from simulations complement experimental results
and help to bring an increased understanding of the studied systems.
Conclusions
The herein-applied NMR methodology,
where 1H NMR spectroscopy
in H2O is combined with appropriate treatment of data,
allows investigation of peptide aggregation with concentration, solution
conditions, and time. Results show that 1H NMR can be used
to detect the presence of coexisting classes of aggregates and inclusion
or exclusion of counterions in peptide aggregates formed. The results
from the AA-MD simulations provide information on the aggregation
behavior on short time scales and information on the amino acid residues
involved in peptide–peptide interactions within aggregates.
The results from NMR and AA-MD simulations correlate well with respect
to aggregation propensity for D-Phe6-GnRH, ozarelix, and
cetrorelix. Taken together, the results from this study illustrate
that both 1H NMR and AA-MD simulations can be useful tools
in evaluation of the aggregation propensity of therapeutic peptides
during developability assessment and early formulation development.
Authors: Pierre Broqua; Pierre J-M Riviere; P Michael Conn; Jean E Rivier; Michel L Aubert; Jean-Louis Junien Journal: J Pharmacol Exp Ther Date: 2002-04 Impact factor: 4.030